TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00484562

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Homefill oxygen delivery system
Description: Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helios oxygen delivery system
Description: Liquid oxygen portable system pre-filled from a larger liquid oxygen tank

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle oxygen system
Description: portable battery-powered oxygen concentrator delivery system
Study: NCT02190032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mallinckrodt endotracheal tube with a modified angle
Description: At sniffing position, the distal tip of a double-lumen tube is located at the patient's cricoid cartilage level and then the tube is bent at the intersection point of oral axis and the pharyngolaryngeal axis with an angle between the two axes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mallinckrodt endobronchial tube with a conventional angle
Description: Inserting a manufacturer-provided conventional-angled tube
Study: NCT02078375

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: whey protein plus casein protein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate (Placebo)
Description: The twice daily placebo will consist of a carbohydrate and a small amount of protein
Study: NCT00762021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SN60AT
Description: Implantation with the AcrySof Intraocular Lens Model SN60AT following cataract removal.
Study: NCT02078375

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Exercise Program
Description: All participants will be enrolled in an individually supervised twice weekly (for 16 weeks) resistance exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Program
Description: All participants will be enrolled in an individually supervised twice weekly (for 16 weeks) resistance exercise program
Study: NCT00762021

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SN60WF
Description: Implantation with the AcrySof Intraocular Lens Model SN60WF following cataract removal.
Study: NCT04925596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePrimaPrescribe online educational program
Description: online training program aiming to change general practitioners' benzodiazepine prescription

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ComunicaSaudeMental online educational program
Description: online training program aiming to improve general practitioners' communication with mentally ill patients
Study: NCT01374802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 400 mg tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Study: NCT00610701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior pin placement
Description: Anteriorly-placed (front of the leg) femoral external fixator pins

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral pin placement
Description: Laterally-placed (side of the leg) femoral external fixator pind
Study: NCT02641457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: 12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 12 eyes received an intraocular injection of 1.25mg ranibizumab and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
Study: NCT03267823

Intervention type: DIAGNOSTIC_TEST
Intervention: International Normal Ratio (INR)
Description: Blood test for INR using laboratory and point of care methods
Study: NCT03317028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS02 tablet and placebo tablet
Description: Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS02 tablet and placebo tablet
Description: Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS02 tablet and placebo tablet
Description: Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CS02 tablet and placebo tablet
Description: Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.
Study: NCT04424875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Description: patients will remove impacted third molar and receive 3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will remove impacted third molar and receive 2 ml hydroxyethyl cellulose gel 2%
Study: NCT00507221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Every 3 months for 24 months (enrollment 3, 6, 9, 12, 15, 18, 21, and 24 months):~400mg/day X 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel
Description: At enrollment and 12 months: 25mg/kg X 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current standard of care in Kenya
Description: Current standard of care for HIV patients in Kenya based on WHO guidelines.
Study: NCT01233609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid
Description: One to four 250mg softgels by mouth daily (dose determined by body weight)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage per subject weight- same schedule as the active comparator
Study: NCT01115543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alfacalcidol and calcitriol
Description: The initial dose of alfacalcidol was twice that of calcitriol.Both were adjusted to control intact PTH within the ranges of 150-300 pg/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfacalcidol and calcitriol
Description: The initial dose of alfacalcidol was twice that of calcitriol.Both were adjusted to control intact PTH within the ranges of 150-300 pg/ml.
Study: NCT02069574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal therapy
Study: NCT00641173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: treatment with SSRI paroxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: treatment with placebo
Study: NCT04080518

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin 10 MG [Forxiga]
Description: 24 Hour Urine Collection, Sodium (23Na) MRI and Magnetic Resonance (MR) spectroscopy scan, Blood collection for metabolomic and osmolyte analysis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 MG [Forxiga]
Description: 24 Hour Urine Collection, Sodium (23Na) MRI and Magnetic Resonance (MR) spectroscopy scan, Blood collection for metabolomic and osmolyte analysis
Study: NCT01084317

Intervention type: OTHER
Intervention: medical documentation and telephone interview
Description: medical documentation analysis supplemented by telephone interview conducted with parents of the child
Study: NCT00203151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: edratide
Description: 0.5 mg, 1.0 mg, 2.5 mg injection once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: edratide
Description: 0.5 mg, 1.0 mg, 2.5 mg injection once weekly
Study: NCT01411722

Intervention type: DEVICE
Group type: OTHER
Intervention: Neurally adjust ventilatory assist (NAVA) and a nasogastric tube to measure the electrical activity of the diaphragm (EAdi catheter)
Description: Nava is a new ventilatory mode which delivers pressure in proportion of the the Electrical activity of the diaphragm (EAdi), a reflection of the neural respiratory output. EAdi will be obtained through a nasogastric tube with a multiple array of electrodes placed at its distal end. Correct positioning of the EAdi catheter is assured by means of a specific function of the ventilator (''EAdi catheter positioning''). The EAdi signal is processed according to the American Thoracic Society (ATS) recommendations and filtered by algorithms designed to provide the highest possible signal-to-noise ratio
Study: NCT00591123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Once every two weeks all patients will receive Oxaliplatin 85 mg/m2 IV, Leucovorin 400 mg/m2 IV and 5-FU 400 mg/m2 IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 2400 mg/m2 IV will be given via pump for 46-48 hours at home.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: All patients will also be given Erlotinib, 100 mg orally daily for the first 4 weeks. Those patients who have not experienced toxicities will increase the dose level to 150 mg daily. Patients who have toxicities will remain at the 100 mg dose level or lower if necessary.
Study: NCT02372864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction (MBSR)
Description: Mindfulness based stress reduction (MBSR) is a standardized eight-week psychosocial intervention delivered by certified trainers. The programme consists of a weekly class of two and half hours for a period of eight weeks and a full retreat day. Furthermore participants are asked to practice exercises at home for 45 minutes, six days a week. The MBSR class will consist of ten to twelve persons, starting at different weekdays and moments of the day. If during the inclusion process it becomes apparent that a group of participants (provided a sufficient group size) comes from a region (e.g. Friesland or Overijssel) with a considerable amount of traveling time to the UMCG, efforts will be made to start a MBSR training in the region with trainers from the UMCG.
Study: NCT03798834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fascia iliaca block (FIB)
Description: ultrasound-guided Fascia iliaca block

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spinal anesthesia
Description: Spinal anaesthesia using 2 ml hyperbaric bupivacaine 0.5%
Study: NCT00549887

Intervention type: DRUG
Intervention: Analog or Human Insulin
Description: prescribed in accordance with usual clinical practice

Intervention type: DRUG
Intervention: Analog or Human Insulin
Description: prescribed in accordance with usual clinical practice
Study: NCT00847990

Intervention type: OTHER
Intervention: Maternal blood screening test for fetal aneuploidy
Description: One blood draw of 20 to 30 mL
Study: NCT00278382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01091896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
Study: NCT04536571

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test Contact lens
Description: Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Contact lens
Description: Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Contact lens
Description: Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Contact lens
Description: Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
Study: NCT00599547

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplantation
Description: Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
Study: NCT01567865

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine produced in existing facility
Description: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine produced in new facility
Description: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine produced in new facility
Description: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine produced in new facility
Description: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China
Study: NCT03274219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bb21217
Description: autologous T cells transduced ex-vivo with anti-BCMA CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA, suspended in cryopreservative solution
Study: NCT02780622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir 75 mg orally, twice daily for 4 days and once on Day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir 75 mg orally, twice daily for 4 days and once on Day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin once daily, at a dose determined through titration by participants' usual hematologist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin once daily, at a dose determined through titration by participants' usual hematologist.
Study: NCT00715572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thyroxine
Description: monotherapy with thyroxine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thyroxine and triiodothyronine
Description: combination with thyroxine and triiodothyronine
Study: NCT01100047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: Oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension
Study: NCT01453478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756
Description: CXCR2 antagonist
Study: NCT04381260

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for patients included in this group as this is a retrospective data registry only.

Intervention type: OTHER
Intervention: Interview
Description: Key Informant Interview

Intervention type: OTHER
Intervention: Survey
Description: Stakeholder survey
Study: NCT04426344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ensoETM device
Description: Core warming will be performed using standard technique per instructions for use for the esophageal heat transfer device. The esophageal heat transfer device will be set to 42°C temperature after initial placement, and maintained at 42°C for the duration of treatment. It is expected that patient temperature will increase from baseline by 1°C to 2°C, but due to ongoing heat loss from the patient, the expected maximum patient temperature is below 39°C. The time course of illness of COVID-19 is such that most patients no longer have fever by the time of mechanical ventilation.\[41\] If patient temperature increases above this range and reaches 39.8°C, the device will be set to an operating temperature of 40°C, thereby preventing any further increase in patient temperature (ambient heat loss precludes patient from reaching device operating temperature).
Study: NCT02042638

Intervention type: DRUG
Intervention: hCG 1500 IU three times a week

Intervention type: DRUG
Intervention: Pregnyl (hCG) ampule 1500 IU/three times a week
Study: NCT02692950

Intervention type: OTHER
Group type: OTHER
Intervention: Honor My Decisions Advance Care Planning Video
Description: Honor My Decisions is a commercial computer application which allows a person to record a video of his/her advanced care planning and legacy information.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Post-video questionnaire
Description: Questions regarding the video process, changes to previous answers and reaction received by others viewing the video
Study: NCT03032874

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: They all had screening colonoscopy

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: They all had screening colonoscopy
Study: NCT02049710

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Seventeen Days
Description: Interactive video includes highlighting salience of active choices in sexual decision making, modeling different responses to sexual situations, cognitive rehearsal of preventive behaviors, and information about hormonal and non-hormonal contraception

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Driving Skills for Life
Description: Interactive video includes guidance and practice for safe driving techniques, driver and car care tips, an eco-driving learning module, and interactive driving games.
Study: NCT01370603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 40 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: 10 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/atorvastatin
Description: Ezetimibe/atorvastatin 10 mg/40 mg combination tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to atorvastatin
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ezetimibe
Description: Administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to ezetimibe/atorvastatin
Description: Administered orally once daily
Study: NCT00136032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Stratified based on age and estrogen status from 3 to 6 mcg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage based on age and estrogen status ranging from 3 to 6 mcg/kg/day
Study: NCT00467064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arthritis Quick Start
Description: Two week, lay led, workshop focusing on goal setting, problem solving, and content specific to disease management.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed treatment intervention
Description: After four months delay, participants in Control Group receive Experimental workshop.

Intervention type: OTHER
Group type: OTHER
Intervention: Delayed treatment intervention
Description: After four months delay, participants in Control Group receive Experimental workshop.
Study: NCT03453827

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT01420263

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Re-feeding residuals
Description: In the presence of significant gastric residuals (more than 1/3 of previous feed or \> 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Feeding Breastmilk or Formula only
Description: In the presence of significant gastric residuals (more than 1/3 of previous feed or \> 2ml), residual volumes will be discarded and fresh breastmilk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
Study: NCT01393041

Intervention type: DEVICE
Group type: OTHER
Intervention: Angio-Seal VIP
Description: Vascular Closure Device
Study: NCT04049292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Better and safer return to sport (BEAST)
Description: The RTS assessment includes a Lachman test, modified stroke test, side hop test, triple hop test, and quadriceps muscle power test. The sport-specific progression plans have 6 participation levels in practice and 6 participation levels in match play. A minimum of 2 weeks and 4 training sessions without pain or effusion must be completed before the athlete progresses to the next level. Criteria for full, unrestricted participation in practice: (1)at least 9 months from ACLR, (2)modified stroke test grade 0, (3)completed previous levels in the sport-specific progression plan, (4)negative Lachman test, (5)side hop test limb symmetry at least 90%, (6)triple hop test limb symmetry at least 90%, (7)quadriceps power symmetry at least 90%. The strength training and knee control exercise protocols each have 3-4 different exercises of 3-4 sets that are performed 3 days per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care is determined by the treating health care professional
Study: NCT00192140

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist
Description: A single intranasal dose of FluMist will be administered to approx. 300 subjects.
Study: NCT01207050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: 8mg capsule taken within one half hour of bedtime each night over the three night study period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control treatment